SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Steve Fancy who wrote (2434)10/21/1997 3:42:00 PM
From: margie  Read Replies (2) of 6136
 
No, I think all the revised earnings and revenues are from U.S. sales of Viracept. On 10/8/97, Paine Webber revised fiscal 1998 EPS estimate to $1.00 from .64, and revised Viracept U.S. sales to $350 million from their previous $325 million. The 98 estimate includes a milestone payment of $11 million from Roche upon European regulatory approval for Viracept, which contributes approximately $0.20 to earnings.

PW increased fiscal 1999 and fiscal 2000 Viracept US sales estimates to $475 million from $464 million and to $559 million from $540 million, respectively, driving fiscal 1999 EPS estimates and fiscal 2000 EPS estimates to $2.31 and $4.00. PW also increased Viracept manufacturing revenues to Roche and royalty income based on earlier than expected Viracept Viracept international sales.

Looks like all the revised revenues and earnings are for
Viracept U.S. revenues.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News